Sanchez-Carpintero R
Unidad de Neurología Pediátrica, Clinica Universitaria de Navarra, Pamplona, Espana.
Rev Neurol. 2011 Jun 1;52(11):681-8.
Alterations in SCN1A gene cause most cases of Dravet syndrome. This finding has increased scientific interest in the syndrome, helping to better define its clinical features and facilitating treatment.
To update the knowledge on Dravet syndrome and to discuss the role of the molecular studies in improving early detection and specific management of the syndrome.
We review the current information on the causes, clinical and electrical characteristics, treatment and complications of Dravet syndrome. Special emphasis is made on early detection.
The phenotype of Dravet syndrome is now better defined and early detection is already possible. As a consequence, it is now possible to use more specific antiepileptic drugs and to avoid harmful treatments. The benefits of better and prompter control of seizures and earlier cognitive interventions need to be demonstrated in prospective studies of children diagnosed in their first year of life.
SCN1A基因的改变导致了大多数Dravet综合征病例。这一发现增加了科学界对该综合征的兴趣,有助于更好地界定其临床特征并促进治疗。
更新关于Dravet综合征的知识,并讨论分子研究在改善该综合征的早期检测和特异性管理方面的作用。
我们回顾了关于Dravet综合征的病因、临床和电生理特征、治疗及并发症的当前信息。特别强调了早期检测。
Dravet综合征的表型现在已得到更好的界定,并且早期检测已成为可能。因此,现在可以使用更具特异性的抗癫痫药物并避免有害治疗。在对出生第一年即被诊断的儿童进行的前瞻性研究中,需要证明更好、更及时地控制癫痫发作以及更早进行认知干预的益处。